Amylin Pharmaceuticals, Inc and Eli Lilly and Company announced results from a randomized, double-blind, cross-over, four-week head-to-head study demonstrating that Byetta (exenatide) injection, a GLP-1 receptor agonist, provided significantly lower glucose levels in the post-meal setting when compared to Januvia (sitagliptin), a DPP-4 inhibitor.
http://www.pharmabiz.com/article/detnews.asp?articleid=46026
No comments:
Post a Comment